Oleoylcarnitine | 13962-05-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Oleoylcarnitine
• 英文别名: 3-[(Z)-octadec-9-enoyl]oxy-4-(trimethylazaniumyl)butanoate
• CAS: 13962-05-5
• 化学式: C25H47NO4
• 分子量: 425.6
• InChiKey: IPOLTUVFXFHAHI-SEYXRHQNSA-N

物化性质

• 熔点：
  >106°C (dec.)
• 溶解度：
  轻微溶于甲醇、加热微溶于水
• 碰撞截面：
  218.73 Ų [M+H]+ [CCS Type: DT, Method: stepped-field]

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  30
• 可旋转键数：
  20
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  66.4
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
  申请人：Merck & Co., Inc.

  公开号：EP0215697A2

  公开（公告）日：1987-03-25

  Acylcarnitine used as a nasal, buccal, sublingual and vaginal drug absorption enhancing vehicle for poorly absorbed drugs.

  酰基肉碱可用作鼻腔、口腔、舌下和阴道药物吸收促进剂，用于吸收不良的药物。
• Markers of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and methods of use thereof
  申请人：Lipomics Technologies, Inc.

  公开号：EP2607902A1

  公开（公告）日：2013-06-26

  Novel methods for assessing the level of triglycerides in the liver of a subject are described, comprising determining the amount of a lipid metabolite in a sample from a body fluid of the subject. The methods may be used, for example, in diagnosing and monitoring liver disorders such as steatosis, NAFLD and NASH.

  本文描述了评估受试者肝脏中甘油三酯水平的新方法，包括确定受试者体液样本中脂质代谢物的含量。这些方法可用于诊断和监测脂肪变性、非酒精性脂肪肝和非酒精性脂肪性肝病等肝脏疾病。
• COMPOSITION CONTAINING ORGANIC AMMONIUM SALT
  申请人：Miyoshi Oil & Fat Co., Ltd.

  公开号：EP3925672A1

  公开（公告）日：2021-12-22

  Provided is a novel composition with excellent stability which contains an organic ammonium salt. The composition containing an organic ammonium salt of the present invention contains an organic ammonium salt having a hydrogen-bonding functional group(s) in a cation and/or an anion, and a surfactant.

  本发明提供了一种稳定性极佳的新型组合物，其中含有一种有机铵盐。 本发明中含有有机铵盐的组合物包含一种在阳离子和/或阴离子中具有氢键官能团的有机铵盐和一种表面活性剂。
• Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps
  申请人：Universal Diagnostics, S.L.

  公开号：US10006925B2

  公开（公告）日：2018-06-26

  Described herein are sets of metabolite and lipid (e.g., fatty acid) markers that can be used in the detection of early stage colorectal cancer and/or early development of adenomatous polyps. Presented herein are illustrative pathology-linked panels. In certain embodiments, the markers presented herein (or subsets thereof) are used as a panel for detecting either colorectal cancer or adenomatous polyps at the same time. The markers presented herein include metabolites and lipids (e.g., fatty acid) freely detectable and accurately quantifiable in human serum. In certain embodiments, the sample may be plasma, urine, saliva, whole blood, dried blood spot or dried serum spot.

  本文介绍了可用于检测早期结直肠癌和/或早期腺瘤性息肉的代谢物和脂质（如脂肪酸）标记物。本文介绍的是与病理学相关的说明性面板。在某些实施方案中，本文提出的标记物（或其子集）可用作同时检测结直肠癌或腺瘤性息肉的面板。本文提出的标记物包括可在人体血清中自由检测和准确量化的代谢物和脂质（如脂肪酸）。在某些实施方案中，样本可以是血浆、尿液、唾液、全血、干血斑或干血清斑。
• Dosing regimens for echinocandin class compounds
  申请人：Cidara Therapeutics, Inc.

  公开号：US10016479B2

  公开（公告）日：2018-07-10

  The invention features pharmaceutical compositions, methods, and kits featuring dosing gimens and oral dosage formulations for administration of echinocandin class compounds.

  本发明的特点是药物组合物、方法和试剂盒，具有给药剂量和口服剂型，用于给药棘白菌素类化合物。